Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol for prevention of cirrhosis decompensation in high-risk CSPH based on liver stiffness
ChiCTR2300073864Phase 4Recruiting
- Sponsor
- Shenyang Sixth People's Hospital
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Cirrhosis and Portal Hypertension (PH) comparing Carvedilol with Placebo (2 arms). Primary endpoints: First decompensation event or liver-related death, Overt ascites and 2 more. Started Jul 2023; status: recruiting.
02
Drugs
carvedilol
03
Conditions
CirrhosisPortal Hypertension (PH)
Beyond the preview
Go deeper on ChiCTR2300073864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073864.